Boston Scientific Corporation

NYSE:BSX Stock Report

Market Cap: US$146.3b

Boston Scientific Future Growth

Future criteria checks 3/6

Boston Scientific is forecast to grow earnings and revenue by 17.7% and 9.4% per annum respectively. EPS is expected to grow by 17.5% per annum. Return on equity is forecast to be 18% in 3 years.

Key information

17.7%

Earnings growth rate

17.5%

EPS growth rate

Medical Equipment earnings growth12.1%
Revenue growth rate9.4%
Future return on equity18.0%
Analyst coverage

Good

Last updated24 Apr 2025

Recent future growth updates

Recent updates

Estimating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)

Apr 23
Estimating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)

Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Apr 07
Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Boston Scientific: Bright Future, Rather Pricey

Mar 18

Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

Mar 05
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

Boston Scientific (NYSE:BSX) Has More To Do To Multiply In Value Going Forward

Jan 29
Boston Scientific (NYSE:BSX) Has More To Do To Multiply In Value Going Forward

Is It Time To Consider Buying Boston Scientific Corporation (NYSE:BSX)?

Jan 15
Is It Time To Consider Buying Boston Scientific Corporation (NYSE:BSX)?

Boston Scientific Standing Apart As A Rare Med-Tech Growth Story

Jan 14

Calculating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)

Jan 02
Calculating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)

Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention?

Dec 19
Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention?

Why The Fundamentals Make Me Bullish On Boston Scientific

Oct 31

Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio

Oct 23

Is Boston Scientific (NYSE:BSX) A Risky Investment?

Oct 10
Is Boston Scientific (NYSE:BSX) A Risky Investment?

Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement

Sep 24
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement

Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors

Sep 20

Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable

Sep 09
Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable

A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Aug 23
A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business

Aug 08
The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business

Boston Scientific Q2 Earnings Preview: Can The Rally Continue?

Jul 17

Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching

Jul 05
Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching

Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?

Jun 21
Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?

Boston Scientific Has Become A Standout Growth Story In Med-Tech

Jun 13

Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Jun 08
Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

May 10
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash

Apr 05
author-image

Axonics and FARAPULSE acquisitions to skyrocket market share and revenue in medical devices

Mar 15 Uncertainty surrounding the approval and U.S. launch timeline for ACURATE neo2 might affect projected revenues from the Structural Heart Valves franchise.

Earnings and Revenue Growth Forecasts

NYSE:BSX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202723,5904,0694,287N/A24
12/31/202621,4543,4743,459N/A32
12/31/202519,4252,7572,701N/A32
3/31/202517,5542,031N/AN/AN/A
12/31/202416,7471,8532,6653,435N/A
9/30/202415,9111,7932,1792,936N/A
6/30/202415,2291,8281,8662,632N/A
3/31/202414,7071,7651,7262,477N/A
12/31/202314,2401,5701,8222,503N/A
9/30/202313,7571,1911,7362,353N/A
6/30/202313,4008611,5592,125N/A
3/31/202313,0458461,2561,774N/A
12/31/202212,6826421,0081,526N/A
9/30/202212,5675966291,197N/A
6/30/202212,3298286681,192N/A
3/31/202212,1627541,0071,528N/A
12/31/202111,8889851,3981,870N/A
9/30/202111,4701,1011,7012,065N/A
6/30/202111,1965261,9392,243N/A
3/31/202110,1222011,6041,869N/A
12/31/20209,913-1151,2191,508N/A
9/30/202010,1083,6851,2421,527N/A
6/30/202010,1573,9801,0081,386N/A
3/31/202010,7854,2879861,409N/A
12/31/201910,7354,7001,4271,836N/A
9/30/201910,3921,0907821,163N/A
6/30/201910,0771,3968261,162N/A
3/31/20199,9371,797148467N/A
12/31/20189,8231,671N/A310N/A
9/30/20189,670670N/A975N/A
6/30/20189,500521N/A926N/A
3/31/20189,267112N/A1,626N/A
12/31/20179,048104N/A1,426N/A
9/30/20178,831843N/A1,418N/A
6/30/20178,714788N/A935N/A
3/31/20178,582435N/A1,059N/A
12/31/20168,386347N/A1,182N/A
9/30/20168,09581N/A835N/A
6/30/20167,878-345N/A1,274N/A
3/31/20167,595-36N/A913N/A
12/31/20157,477-239N/A691N/A
9/30/20157,314-396N/A711N/A
6/30/20157,272-155N/A649N/A
3/31/20157,302-253N/A874N/A
12/31/20147,308-119N/A1,269N/A
9/30/20147,258288N/A1,104N/A
6/30/20147,147240N/A1,009N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BSX's forecast earnings growth (17.7% per year) is above the savings rate (2.8%).

Earnings vs Market: BSX's earnings (17.7% per year) are forecast to grow faster than the US market (13.9% per year).

High Growth Earnings: BSX's earnings are forecast to grow, but not significantly.

Revenue vs Market: BSX's revenue (9.4% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: BSX's revenue (9.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BSX's Return on Equity is forecast to be low in 3 years time (18%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/24 16:51
End of Day Share Price 2025/04/24 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Boston Scientific Corporation is covered by 68 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
David RescottBaird
Adam FeinsteinBarclays